Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 20/20 | 1.00 |
| ▸ | F10 | P00742 | 16/20 | 0.78 |
| ▸ | F2 | P00734 | 12/20 | 0.78 |
| ▸ | PLG | P00747 | 12/20 | 0.78 |
| ▸ | PLAU | P00749 | 12/20 | 0.78 |
| ▸ | TMPRSS6 | Q8IU80 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12998800 | 1.00 | ST14 (1.00) | ST14F10F2PLGPLAU | |
| SCHEMBL12998793 | 0.90 | ST14 (1.00) | ST14F10F2PLGPLAU | |
| SCHEMBL19545496 | 0.85 | ST14 (0.74) | ST14F10F2PLGPLAU | |
| SCHEMBL12998795 | 0.84 | ST14 (1.00) | ST14F10F2PLGPLAU | |
| SCHEMBL8187987 | 0.84 | ST14 (1.00) | ST14F10F2PLGPLAU | |
| SCHEMBL8196584 | 0.83 | F10 (1.00) | ST14F10F2PLGPLAU | |
| SCHEMBL12998731 | 0.81 | F10 (1.00) | ST14F10F2PLGPLAU | |
| SCHEMBL8201668 | 0.81 | ST14 (1.00) | ST14F10F2PLGPLAU | |
| SCHEMBL8196664 | 0.80 | ST14 (1.00) | ST14F10F2PLGPLAU | |
| SCHEMBL12998792 | 0.80 | ST14 (1.00) | ST14F10F2PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208308-B2 | Matriptase inhibitors and uses thereof against orthomyxoviridae infections | SOCPRA Sciences Sante et Humaines S.E.C. (CA) | 2019-02-19 | — | — | US | disclosed |
| US-20170314023-A1 | MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS | UNIVERSITE DE SHERBROOKE (CA) | 2017-11-02 | — | — | US | disclosed |
| US-9752149-B2 | Matriptase inhibitors and uses thereof against orthomyxoviridae infections | SOCPRA Sciences Sante et Humaines S.E.C. (CA) | 2017-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208308-B2 | Matriptase inhibitors and uses thereof against orthomyxoviridae infections | MMP7, MATR3, ADAMTS1 | ST14 96/4885F10 321/4885F2 995/4885 |
| US-20170314023-A1 | MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS | MMP7, MATR3, ADAMTS1 | ST14 96/4885F10 321/4885F2 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.